Assessing the photocatalytic degradation of fluoroquinolone norfloxacin by Mn:ZnS quantum dots: Kinetic study, degradation pathway and influencing factors

SR/WOS-A/CS-82/2018 UIDB/50006/2020Norfloxacin (NOFX), a broadly used fluoroquinolone antibiotic, has been a subject of great concern in the past few years due to its undesirable effect on human beings and aquatic ecosystems. In this study, novel Mn doped ZnS (Mn:ZnS) quantum dots (QDs) were prepared through a facile chemical precipitation method and used as photocatalysts for NOFX degradation. Prior to photodegradation experiments, morphological and optical parameters of the QDs were examined through transmission electron microscopy, scanning electron microscopy, energy dispersive X-ray analysis, Fourier transform infrared spectroscopy, ultraviolet-visible spectroscopy, fluorescence spectroscopy, Brunauer–Emmett–Teller analysis, and differential thermal and thermogravimetric analyses. Mn:ZnS QDs exhibited excellent properties of photodegradation, not only under UV irradiation but also in sunlight, which induced NOFX to photodegrade. The utmost photodegradation efficiency was obtained under optimal conditions (25 mL of NOFX, 15 mg/L, pH 10, 60 min UV irradiation, 60 mgs QDs), adopting first order kinetics. In addition, hydroxyl radicals produced by the conduction band electrons were found to be the primary reason dominating the transformation of NOFX in basic conditions, while holes, oxygen atoms, as well as the doped metal (Mn) enhanced the degradation. The QDs showed excellent reusability and stability in four repeated cycles. Finally, four different pathways were predicted, derived from the identified intermediates, with piperazinyl ring transformation being the primary one. It is expected that the synthesized Mn:ZnS QDs could be utilized as efficient photocatalytic materials for energy conversion and ecological remediation.publishersversionpublishe

Differential Calcium Dependence of Axonal Versus Somatodendritic Dopamine Release, with Characteristics of Both in the Ventral Tegmental Area

Midbrain dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) exhibit somatodendritic release of DA. Previous studies indicate a difference between the Ca2+ dependence of somatodendritic DA release in the SNc and that of axonal DA release in dorsal striatum. Here, we evaluated the Ca2+ dependence of DA release in the VTA and nucleus accumbens (NAc) shell for comparison with that in the SNc and dorsal striatum. Release of DA was elicited by single-pulse stimulation in guinea-pig brain slices and monitored with subsecond resolution using carbon-fiber microelectrodes and fast-scan cyclic voltammetry. In dorsal striatum and NAc, DA release was not detectable at extracellular Ca2+ concentrations ([Ca2+]o) below 1 mM; however, a progressive increase in evoked extracellular DA concentration ([DA]o) was seen with [Ca2+]o ≥ 1.5 mM. By contrast, in SNc and VTA, robust increases in [DA]o could be elicited in 0.25 mM [Ca2+]o that were ∼60% of those seen in 1.5 mM [Ca2+]o. In SNc, a plateau in single-pulse evoked [DA]o was seen at [Ca2+]o ≥ 1.5 mM, mirroring the release plateau reported previously for pulse-train stimulation in SNc. In VTA, however, evoked [DA]o increased progressively throughout the range of [Ca2+]o tested (up to 3.0 mM). These functional data are consistent with the microanatomy of the VTA, which includes DA axon collaterals as well as DA somata and dendrites. Differences between axonal and somatodendritic release data were quantified using Hill analysis, which showed that the Ca2+ dependence of axonal DA release is low affinity with high Ca2+ cooperativity, whereas somatodendritic release is high affinity with low cooperativity. Moreover, this analysis revealed the dual nature of DA release in the VTA, with both somatodendritic and axonal contributions

Effect of different storage conditions and seed treatments on seed viability in soybean [Glycine max (L.) Merr.]

The present investigation was carried out in laboratory of the Department of Seed Science and Technolo-gy, College of Agriculture, Junagadh Agricultural University, Junagadh from the April 2013 to April 2015, wherein two kg of freshly harvested quality seed of soybean cv. Gujarat Junagadh Soybean 3 having high germination percentage and low moisture content (below 8%) was taken for each repetition and for each combination of treat-ments. The treatment consisted of two storage conditions (C) viz., C1 (Ambient temperature) and C2 (Cold storage at 7oC + 2oC), and five seed treatments (S) viz., S1 = Control, S2 = Carbendazim @ 2g/kg seed, S3 = Mancozeb @ 2g/ kg seed, S4 = Neem leaf powder @ 10g/kg seed, and S5 = Neem Oil @ 5 ml/kg seed. The experiment was carried out using Completely Randomized Design (Factorial) repeated three times. After proper mixing or smearing the seeds as per the treatments, seeds were packed in cloth bag and kept in laboratory under two different storage conditions. Observations were recorded at 90 days interval on germination (%), root length (cm), shoot length (cm), seedling dry weight (g), seed vigour index I, seed vigour index II and seed moisture content (%). The results revealed that storage condition (C) and seed treatments (S) exhibited significant differences almost for the all the traits for germination and seedling parameters after 2 years of storage. The results of soybean seed stored in two different storage conditions showed that on an average, the seed stored under cold storage (70C + 20C) noted higher values for all the traits studied except seed moisture content after 2 years of storage. Among the seed treatments, on an average, after 2 years of seed storage, significantly (P<0.05) higher values were recorded by all the seed treatments over the control. However, seed treated with Mancozeb @ 2g/kg of seed recorded the significantly highest germination percentage (71.50 %) and it was at par with Neem leaf powder @ 10 g / kg seed (70.67%) and Carbendazim @ 2g /kg seed (69.67%) after 2 years of storage. The germination percentage noted in control treatment was 33.17 per cent after 2 years of storage. An ISTA standard for germination in soybean is 70 per cent. Most of the interactions effects were found significant (P<0.05) for all the traits studied

Effect of storage conditions, packing materials and seed treatments on viability and seedling vigour of onion (Allium cepa l.) seeds

The present investigation was carried out from July 2013 to July 2015, wherein 100 g of fresh quality seed of onion cv. GWO 1 was having high germination percentage and moisture content below 8 per cent. The treatment consisted of two storage conditions (C) viz., C1 (Ambient temperature) and C2 (Cold storage at 70C + 20C); two packing materials (P) viz., P1 = Cloth Bag and P2 = Polythene Bag (500 gauge = 125 µ), and five seed treatments (S) viz., S1 = Control, S2 = Carbendazim @ 2g/kg seed, S3 = Mancozeb @ 2g/kg seed, S4 = Thirum @ 3g/kg seed, and S5 = Neem leaf powder @ 10g / kg seed. After proper mixing or smearing the seeds as per the treatments, seeds were packed and stored as per treatments. Observations were recorded at 90 days interval on viability and vigour parameters. The results revealed that seed stored under cold storage (7±2 °C) and in polyethylene bags (500 gauge) noted significantly higher values for all the characters even after two years of storage. All the treatment combinations of seed stored under cold storage gave more than 70 per cent germination (As per ISTA standard) even after two years of storage, of which, seed treated with thirum @ 3g/kg seed was the best treatment. Therefore, it can be concluded that seed of onion can be stored up to two year in cold storage packed in polyethylene bag without or with seed treatment without deterioration in germination and seedling vigour

Permanent Nonselective His Bundle Pacing in an Adult with L-Transposition of the Great Arteries and Complete AV Block

We report the placement of a permanent transvenous nonselective His bundle pacing lead in conjunction with a transvenous pacemaker/implantable cardioverter-defibrillator in an adult with Levo-Transposition of the Great Arteries (L-TGA) and a stenotic coronary sinus (CS) ostium, which would not accommodate a transvenous left ventricular (LV) pacing lead. Nonselective His bundle pacing provided a nearly identical ventricular activation pattern in this previously unpaced patient. Many L-TGA patients will have an eventual need for permanent pacing and, given the challenges of CS cannulation, His bundle pacing may represent a preferred modality rather than pure morphologic LV pacing or surgical systemic ventricular lead placement to achieve optimal electrical synchrony

Solochrome dark blue azo dye removal by sonophotocatalysis using mn2+ doped zns quantum dots

Funding Information: Funding: J.P. is thankful to DST, New Delhi, India for Research fellowship under Women Scientist Scheme (SR/WOS-A/CS-82/2018). This work has also been supported by FCT—Fundação para a Ciência e a Tecnologia, I.P., under the Scientific Employment Stimulus-Institutional Call (CEEC-INST/00102/2018) and the Associate Laboratory for Green Chemistry-LAQV which is financed by national funds from FCT/MCTES (UIDB/50006/2020 and UIDP/50006/2020). Funding Information: J.P. is thankful to DST, New Delhi, India for Research fellowship under Women Scientist Scheme (SR/WOS-A/CS-82/2018). This work has also been supported by FCT?Funda??o para a Ci?ncia e a Tecnologia, I.P., under the Scientific Employment Stimulus-Institutional Call (CEEC-INST/00102/2018) and the Associate Laboratory for Green Chemistry-LAQV which is financed by national funds from FCT/MCTES (UIDB/50006/2020 and UIDP/50006/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.This work investigates the degradation of the azo dye solochrome dark blue (SDB) by measurement of the photocatalytic, sonocatalytic and sonophotocatalytic activities, under low ultrasonic frequency (40 kHz) and UV-C (254 nm) light, using Mn-doped ZnS semiconductor quantum dots (Mn2+:ZnS Qds) as catalysts, prepared by a simple chemical precipitation procedure. In order to study the different morphological and optical crystal properties, various characterization techniques were used, such as high resolution transmission electron microscopy, scanning electron microscopy, energy dispersive X-ray analysis, X-ray diffraction, N2 adsorption-desorption at −196 °C and ultraviolet-visible spectroscopy. The average particle size of the semiconductor Qds was in the range of 3–4 nm. The optimal parameters affecting dye degradation, such as the catalyst loading, solution pH, time of irradiation, initial concentration of dye, dopant concentration, ultrasonic power and frequency effect were evaluated. The synthesized catalytic material exhibited a high activity for sonophotocatalytic degradation of SDB (89%), larger than that observed for sonocatalysis (69.7%) or photocatalysis (55.2%) alone, which was due to the improved electron-holes separation, formation of more reactive radicals and enhancement of the active surface area. Qds showed good stability and reusability after five repeated cycles. Finally, the degradation products were identified by liquid chromatography-mass spectrometry (LC-MS).publishersversionpublishe

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health

Cleavage of pyrene-stabilized RNA bulge loops by trans-(±)-cyclohexane-1,2-diamine

Chemical agents that cleave HIV genome can be potentially used for anti-HIV therapy. In this report, the cleavage of the upper stem-loop region of HIV-1 TAR RNA was studied in a variety of buffers containing organic catalysts. trans-(±)-Cyclohexane-1,2-diamine was found to cleave the RNA with the highest activity (31%, 37°C, 18 h). Cleavage of the RNA in trans-(±)-cyclohexane-1,2-diamine buffer was also studied when the RNA was hybridized with complementary DNAs. A pyrene-modified C3 spacer was incorporated to the DNA strand to facilitate the formation of a RNA bulge loop in the RNA/DNA duplex. In contrast, unmodified DNAs cannot efficiently generate RNA bulge loops, regardless of the DNA sequences. The results showed that the pyrene-stablized RNA bulge loops were efficiently and site-specifically cleaved by trans-(±)-cyclohexane-1,2-diamine

Liver X receptors are required for thymic resilience and T cell output

The thymus is a primary lymphoid organ necessary for optimal T cell development. Here, we show that liver X receptors (LXRs)-a class of nuclear receptors and transcription factors with diverse functions in metabolism and immunity-critically contribute to thymic integrity and function. LXRαβ-deficient mice develop a fatty, rapidly involuting thymus and acquire a shrunken and prematurely immunoinhibitory peripheral T cell repertoire. LXRαβ's functions are cell specific, and the resulting phenotypes are mutually independent. Although thymic macrophages require LXRαβ for cholesterol efflux, thymic epithelial cells (TECs) use LXRαβ for self-renewal and thymocytes for negative selection. Consequently, TEC-derived LXRαβ protects against homeostatic premature involution and orchestrates thymic regeneration following stress, while thymocyte-derived LXRαβ limits cell disposal during negative selection and confers heightened sensitivity to experimental autoimmune encephalomyelitis. These results identify three distinct but complementary mechanisms by which LXRαβ governs T lymphocyte education and illuminate LXRαβ's indispensable roles in adaptive immunity

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced or metastatic NSCLC with a confirmed MET exon 14 skipping mutation. The primary end point was the objective response by independent review among patients who had undergone at least 9 months of follow-up. The response was also analyzed according to whether the presence of a MET exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of January 1, 2020, a total of 152 patients had received tepotinib, and 99 patients had been followed for at least 9 months. The response rate by independent review was 46% (95% confidence interval [CI], 36 to 57), with a median duration of response of 11.1 months (95% CI, 7.2 to could not be estimated) in the combined-biopsy group. The response rate was 48% (95% CI, 36 to 61) among 66 patients in the liquid-biopsy group and 50% (95% CI, 37 to 63) among 60 patients in the tissue-biopsy group; 27 patients had positive results according to both methods. The investigator-assessed response rate was 56% (95% CI, 45 to 66) and was similar regardless of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment. CONCLUSIONS: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.)